Last 12 months
Inside the activity.
6 purchase rows · 9 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 6 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2020 Filed Jun 10, 2020 20:15 UTC |
Gould Robert JDirector · See Remarks
|
SaleCommon Stock | 156 | $20.00 | $3,120.00 |
DisclosureSEC source: 0000899243-20-015959 · doc4.xml · nonDerivative · entry 1 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,845 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:17 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionStock Option (right to buy) · Derivative | 451 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-015623 · doc4.xml · derivative · entry 6 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,137 Underlying: Common Stock · 451 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F4 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:17 UTC |
Cadavid DiegoSVP Clinical Development
|
SaleCommon Stock | 451 | $20.18 | $9,100.77 |
DisclosureSEC source: 0000899243-20-015623 · doc4.xml · nonDerivative · entry 4 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $20.31, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:17 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionCommon Stock | 451 | $4.83 | $2,178.33 |
DisclosureSEC source: 0000899243-20-015623 · doc4.xml · nonDerivative · entry 3 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:16 UTC |
Gould Robert JDirector · See Remarks
|
SaleCommon Stock | 3,433 | $20.17 | $69,251.16 |
DisclosureSEC source: 0000899243-20-015784 · doc4.xml · nonDerivative · entry 1 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,001 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.31, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 20:26 UTC |
Gould Robert JDirector · See Remarks
|
SaleCommon Stock | 1,300 | $20.04 | $26,057.98 |
DisclosureSEC source: 0000899243-20-015437 · doc4.xml · nonDerivative · entry 2 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,434 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:17 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionStock Option (right to buy) · Derivative | 226 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-015623 · doc4.xml · derivative · entry 5 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,588 Underlying: Common Stock · 226 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F4 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:17 UTC |
Cadavid DiegoSVP Clinical Development
|
SaleCommon Stock | 226 | $20.05 | $4,531.25 |
DisclosureSEC source: 0000899243-20-015623 · doc4.xml · nonDerivative · entry 2 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:17 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionCommon Stock | 226 | $4.83 | $1,091.58 |
DisclosureSEC source: 0000899243-20-015623 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionStock Option (right to buy) · Derivative | 338 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-015245 · doc4.xml · derivative · entry 6 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,814 Underlying: Common Stock · 338 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC |
Cadavid DiegoSVP Clinical Development
|
SaleCommon Stock | 338 | $20.18 | $6,819.59 |
DisclosureSEC source: 0000899243-20-015245 · doc4.xml · nonDerivative · entry 4 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.41, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionCommon Stock | 338 | $4.83 | $1,632.54 |
DisclosureSEC source: 0000899243-20-015245 · doc4.xml · nonDerivative · entry 3 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 20:26 UTC |
Gould Robert JDirector · See Remarks
|
SaleCommon Stock | 1,500 | $20.13 | $30,192.45 |
DisclosureSEC source: 0000899243-20-015437 · doc4.xml · nonDerivative · entry 1 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,734 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.41, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 20:17 UTC |
Gould Robert JDirector · See Remarks
|
SaleCommon Stock | 2,797 | $20.00 | $55,940.00 |
DisclosureSEC source: 0000899243-20-015063 · doc4.xml · nonDerivative · entry 2 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,234 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:16 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionStock Option (right to buy) · Derivative | 45 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-015245 · doc4.xml · derivative · entry 5 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,152 Underlying: Common Stock · 45 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:16 UTC |
Cadavid DiegoSVP Clinical Development
|
SaleCommon Stock | 45 | $20.00 | $900.00 |
DisclosureSEC source: 0000899243-20-015245 · doc4.xml · nonDerivative · entry 2 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:16 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionCommon Stock | 45 | $4.83 | $217.35 |
DisclosureSEC source: 0000899243-20-015245 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:17 UTC |
Gould Robert JDirector · See Remarks
|
SaleCommon Stock | 5 | $20.00 | $100.00 |
DisclosureSEC source: 0000899243-20-015063 · doc4.xml · nonDerivative · entry 1 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,031 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 20:15 UTC |
Gould Robert JDirector · See Remarks
|
SaleCommon Stock | 1,390 | $20.08 | $27,910.78 |
DisclosureSEC source: 0000899243-20-014721 · doc4.xml · nonDerivative · entry 2 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,036 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.22, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 20:16 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionStock Option (right to buy) · Derivative | 200 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-014722 · doc4.xml · derivative · entry 6 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,197 Underlying: Common Stock · 200 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 20:16 UTC |
Cadavid DiegoSVP Clinical Development
|
SaleCommon Stock | 200 | $20.04 | $4,007.00 |
DisclosureSEC source: 0000899243-20-014722 · doc4.xml · nonDerivative · entry 4 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.07, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 20:16 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionCommon Stock | 200 | $4.83 | $966.00 |
DisclosureSEC source: 0000899243-20-014722 · doc4.xml · nonDerivative · entry 3 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:15 UTC |
Gould Robert JDirector · See Remarks
|
SaleCommon Stock | 1,919 | $20.01 | $38,391.13 |
DisclosureSEC source: 0000899243-20-014721 · doc4.xml · nonDerivative · entry 1 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,426 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:16 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionStock Option (right to buy) · Derivative | 600 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-014722 · doc4.xml · derivative · entry 5 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,397 Underlying: Common Stock · 600 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:16 UTC |
Cadavid DiegoSVP Clinical Development
|
SaleCommon Stock | 600 | $20.00 | $12,000.00 |
DisclosureSEC source: 0000899243-20-014722 · doc4.xml · nonDerivative · entry 2 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:16 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionCommon Stock | 600 | $4.83 | $2,898.00 |
DisclosureSEC source: 0000899243-20-014722 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:15 UTC |
Wallace Owen B.Chief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,232 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-20-014719 · doc4.xml · derivative · entry 3 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,034 Underlying: Common Stock · 2,232 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:15 UTC |
Wallace Owen B.Chief Scientific Officer
|
SaleCommon Stock | 2,232 | $20.00 | $44,640.00 |
DisclosureSEC source: 0000899243-20-014719 · doc4.xml · nonDerivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:15 UTC |
Wallace Owen B.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,232 | $7.84 | $17,498.88 |
DisclosureSEC source: 0000899243-20-014719 · doc4.xml · nonDerivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:15 UTC |
Wallace Owen B.Chief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 448 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-20-014552 · doc4.xml · derivative · entry 3 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,266 Underlying: Common Stock · 448 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:15 UTC |
Wallace Owen B.Chief Scientific Officer
|
SaleCommon Stock | 448 | $20.00 | $8,960.00 |
DisclosureSEC source: 0000899243-20-014552 · doc4.xml · nonDerivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:15 UTC |
Wallace Owen B.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 448 | $7.84 | $3,512.32 |
DisclosureSEC source: 0000899243-20-014552 · doc4.xml · nonDerivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:15 UTC |
Gould Robert JDirector · See Remarks
|
SaleCommon Stock | 2,500 | $20.00 | $50,000.00 |
DisclosureSEC source: 0000899243-20-014415 · doc4.xml · nonDerivative · entry 1 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,345 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:16 UTC |
Wallace Owen B.Chief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 412 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-20-014416 · doc4.xml · derivative · entry 3 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,714 Underlying: Common Stock · 412 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:16 UTC |
Wallace Owen B.Chief Scientific Officer
|
SaleCommon Stock | 412 | $20.00 | $8,240.00 |
DisclosureSEC source: 0000899243-20-014416 · doc4.xml · nonDerivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:16 UTC |
Wallace Owen B.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 412 | $7.84 | $3,230.08 |
DisclosureSEC source: 0000899243-20-014416 · doc4.xml · nonDerivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| May 12, 2020 Filed May 12, 2020 20:15 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,860 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-012822 · doc4.xml · derivative · entry 3 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,997 Underlying: Common Stock · 1,860 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| May 12, 2020 Filed May 12, 2020 20:15 UTC |
Cadavid DiegoSVP Clinical Development
|
SaleCommon Stock | 1,860 | $18.00 | $33,480.00 |
DisclosureSEC source: 0000899243-20-012822 · doc4.xml · nonDerivative · entry 2 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| May 12, 2020 Filed May 12, 2020 20:15 UTC |
Cadavid DiegoSVP Clinical Development
|
Exercise / conversionCommon Stock | 1,860 | $4.83 | $8,983.80 |
DisclosureSEC source: 0000899243-20-012822 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:15 UTC |
Thomson Peter G.VP Finance & Accounting
|
SaleCommon Stock | 7,500 | $16.00 | $120,000.00 |
DisclosureSEC source: 0000899243-20-012820 · doc4.xml · nonDerivative · entry 1 Thomson Peter G. · CIK 0001779120 · VP Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,071 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document |
| March 02, 2020 Filed Mar 2, 2020 23:42 UTC |
Cadavid DiegoSVP Clinical Development
|
SaleCommon Stock | 315 | $18.13 | $5,709.53 |
DisclosureSEC source: 0000899243-20-006590 · doc4.xml · nonDerivative · entry 2 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.45, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 02, 2020 Filed Mar 2, 2020 23:42 UTC |
Cadavid DiegoSVP Clinical Development
|
SaleCommon Stock | 1,828 | $17.26 | $31,545.25 |
DisclosureSEC source: 0000899243-20-006590 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,100 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.91 to $17.85, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 19:52 UTC |
Thomson Peter G.VP Finance & Accounting
|
SaleCommon Stock | 250 | $18.61 | $4,653.00 |
DisclosureSEC source: 0000899243-20-005958 · doc4.xml · nonDerivative · entry 3 Thomson Peter G. · CIK 0001779120 · VP Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,571 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.29 to $19.01, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 19:52 UTC |
Thomson Peter G.VP Finance & Accounting
|
SaleCommon Stock | 2,102 | $17.43 | $36,643.33 |
DisclosureSEC source: 0000899243-20-005958 · doc4.xml · nonDerivative · entry 2 Thomson Peter G. · CIK 0001779120 · VP Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,821 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.95, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 19:52 UTC |
Thomson Peter G.VP Finance & Accounting
|
SaleCommon Stock | 2,648 | $16.18 | $42,856.56 |
DisclosureSEC source: 0000899243-20-005958 · doc4.xml · nonDerivative · entry 1 Thomson Peter G. · CIK 0001779120 · VP Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,923 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.91, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:24 UTC |
Gould Robert JDirector · See Remarks
|
SaleCommon Stock | 2,500 | $20.00 | $50,000.00 |
DisclosureSEC source: 0000899243-20-005300 · doc4.xml · nonDerivative · entry 1 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,845 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:23 UTC |
Wallace Owen B.Chief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,088 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-20-005299 · doc4.xml · derivative · entry 3 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,126 Underlying: Common Stock · 6,088 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:23 UTC |
Wallace Owen B.Chief Scientific Officer
|
SaleCommon Stock | 6,088 | $20.00 | $121,760.00 |
DisclosureSEC source: 0000899243-20-005299 · doc4.xml · nonDerivative · entry 2 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:23 UTC |
Wallace Owen B.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 6,088 | $7.84 | $47,729.92 |
DisclosureSEC source: 0000899243-20-005299 · doc4.xml · nonDerivative · entry 1 Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:31 UTC |
Cadavid DiegoSVP Clinical Development
|
SaleCommon Stock | 2,143 | $17.33 | $37,141.83 |
DisclosureSEC source: 0000899243-20-003272 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,928 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.06 to $17.75, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.